A*STAR Bioinformatics Institute (A*STAR BII)

Antibodies in mucous membranes may be key in protecting against SARS-CoV-2 variants, pointing to the need for COVID-19 vaccines that target these antibody responses.

A high-resolution study of SARS-CoV-2 antibodies revealed how they neutralise variants and reduce the impact of spike protein mutations.

A new machine learning model identifies key dementia features from complex clinical datasets, potentially making diagnoses faster and less subjective.

Innovative designer molecules called stapled peptides effectively target and block cancer processes, promising a new therapeutic approach.

High-resolution simulations uncover dynamic regions on the surface of dengue-like viruses to guide the design of novel antivirals.

Using artificial intelligence techniques, Mai Chan Lau maps the spatial relationships between tumour cells and immune cells to understand their effect on clinical outcomes.

A*STAR frontiers in the national push for a quantum computing advantage

Smartwatch data points to a connection between physical activity and prolonged COVID-19 symptoms among healthcare workers.

Through innovative technologies and deep biological insights, A*STAR research institutes and ecosystem partners aim to enhance the healthspan of Asia’s ageing populations.

A*STAR researchers develop a new method to study RNA’s intricate folding patterns within a single cell, revealing fresh insights into how cells develop and function.

A*STAR researchers developed specially designed nanocomplexes that effectively target and kill cancer cells, including those resistant to traditional treatments.

Researchers identify predictive immune ‘signatures’ in liver cancer patients that can help tailor and improve the success rates of combined immunotherapy and radiotherapy.